Skip to main content
THERAGEN ETEX CO.,LTD. logo

THERAGEN ETEX CO.,LTD. — Investor Relations & Filings

Ticker · 066700 ISIN · KR7066700006 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2025-02-26 Earnings Release
Country KR South Korea
Listing KO 066700

About THERAGEN ETEX CO.,LTD.

http://www.theragenetex.com/

THERAGEN ETEX CO.,LTD. is a biotechnology and pharmaceutical group focused on genome-based personalized and precision medicine. The company integrates advanced genomic analysis with pharmaceutical development and manufacturing. Its genomics division provides comprehensive genetic analysis services, leveraging pioneering achievements such as creating the world's first female and tiger genome maps and commercializing Asia's first individual genome analysis service. The pharmaceutical division develops and supplies medicines from its international GMP-certified facilities. The R&D pipeline focuses on incrementally modified drugs, orphan drugs, and novel anticancer therapies, including its proprietary drug candidate, Vactosertib, which is in clinical trials for various cancers.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a significant change in financial results (30% or more change in revenue or profit/loss). This is a standard disclosure requirement for listed companies in Korea to report preliminary financial results before the final audit report is published. Since it provides key financial highlights and explains the reasons for the change, it falls under the Earnings Release (ER) category. FY 2024
2025-02-26 Korean
소송등의판결ㆍ결정
Legal Proceedings Report Classification · 100% confidence The document is a formal announcement regarding a court decision ('소송등의판결ㆍ결정') concerning a 'prohibition of new share issuance' (신주발행금지가처분). It details the case name, court, and the ruling (dismissal of the application). This falls under the category of legal proceedings and regulatory disclosures regarding litigation outcomes.
2025-02-14 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for the company Theragen Etex. It details the amendment of payment dates, share issuance details, and the purpose of the capital increase (third-party allocation). This falls under the category of announcements regarding new share issues or capital changes.
2025-02-12 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and specifically details a 'Correction Report' (정정신고) for previously filed information. It outlines changes to bond maturity dates, conversion periods, and payment dates. In the context of financial filings, reports detailing the issuance, terms, or amendments of debt instruments like convertible bonds are classified under Capital/Financing Updates.
2025-02-12 Korean
주요사항보고서(소송등의제기)
Legal Proceedings Report Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the filing of a lawsuit (신주발행금지가처분 - Injunction against new share issuance). It details the nature of the legal proceedings, the court involved, and the company's planned response. This fits the definition of a Legal Proceedings Report (LTR) as it concerns significant litigation/regulatory actions.
2025-02-06 Korean
교환사채(해외교환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (TerraGen Etex) detailing the acquisition of exchangeable bonds before their maturity date. It specifies the bond details, acquisition amount, reason for acquisition (mutual agreement), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt management. Given the specific nature of the filing regarding bond acquisition/redemption, it fits best under the 'CAP' (Capital/Financing Update) category.
2025-01-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.